BIOGEN POSTS RECORD REVENUESBiogen Inc. (NASDAQ:BGEN) of Cambridge, Mass., attributed itsrecord revenues for the year to significant increases inroyalties on sales of alpha interferon and hepatitis B vaccinesand diagnostic products.

"Schering-Plough (Corp.), Biogen's licensee for alpha interferon,achieved an almost twofold increase in sales for Intron A in1990 as compared to 1989," said Jim Vincent, Biogen'schairman and chief executive officer.

Fourth quarter ended Dec. 31(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues 16,128 12,304 +31Net income 2,575 1,590 +62Net income per share .04 .01 +300Outstanding shares 26,043 22,483 +16

Year ended Dec. 31(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues 59,415 40,894 +45Net income 7,720 3,214 +140Net income per share .07 .01 +600Outstanding shares 25,430 22,382 +14

GENETICS INSTITUTE BLAMES LOSS ON EPO DELAY

Despite marked improvement in the fourth quarter, GeneticsInstitute Inc. (NASDAQ:GENI) of Cambridge, Mass., said a large1990 loss was partly due to an unexpected delay of U.S.marketing approval for its erythropoietin (EPO) product andthe termination of a development agreement with BurroughsWellcome Co. for GI's plasminogen activator product.

Fourth quarter ended Nov. 30(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues 13,244 8,300 +60Op income (loss) (3,819) (18,448) +79Net income (loss) (2,658) (16,378) +84Net income per share (loss) (.27) (1.23) +78Outstanding shares 14,368 14,133 +2

Year ended Nov. 30(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues 40,374 43,644 -7Op income (loss) (28,393) (36,529) +22Net income (loss) (22,873) (28,737) +20Net income per share (loss) (1.93) (2.11) +9Outstanding shares 14,270 14,062 +1

COLLAGEN PROFITS TAKE A DIVE

Collagen Corp. (NASDAQ:CGEN) of Palo Alto, Calif., explained asharp falloff in profits by saying "earnings continue to benegatively affected by the delayed spinoff of our CeltrixLaboratories subsidiary." Collagen, which had hoped tocomplete the Celtrix spinoff in late 1990, plans for a launch thisyear. Among the bright spots, Collagen said that six-monthsales for its Target Therapeutics unit rose 42 percent. For thesecond quarter, sales were nearly $3.4 million.

First quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues 14,627 11,851 +23Net income 620 1,151 -46Net income per share .07 .13 -46Outstanding shares 9,458 8,912 +6

(c) 1997 American Health Consultants. All rights reserved.

No Comments